Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The attention deficit hyperactivity disorder (ADHD) treatment market was valued at USD 15.39 Billion in 2025, driven by heightened awareness of ADHD among people across the 8 major markets. The market is expected to grow at a CAGR of 5.10% during the forecast period of 2026-2035, with values likely to reach USD 25.31 Billion by 2035.
Base Year
Historical Period
Forecast Period
The market demand for ADHD treatment is increasing as the number of diagnosed ADHD cases has collectively risen across the major markets.
Rising awareness among parents about the brain disorder is significantly contributing to the market growth of the treatment.
The market value is influenced by the escalating number of FDA approvals for the management of the condition.
Compound Annual Growth Rate
5.1%
Value in USD Billion
2026-2035
*this image is indicative*
Attention deficit hyperactivity disorder (ADHD) is a brain disorder which hampers the ability of a person to pay attention to things, along with behaviour control. It is among the most common brain disorders diagnosed in children. Both children and adults are affected by the condition, however, it is commonly diagnosed in children which further continues to adulthood.
Rising Incidence of the Disease
The increasing rates of ADHD diagnoses are highly contributing to the increased demand for ADHD treatment. However, the reason behind the heightening number of ADHD diagnoses is the increasing recognition of the condition. Parents are paying more attention to their children, therefore, the diagnosis rate of the condition is rising. As per the report published by the Centers for Disease Control and Prevention in May 2024, 1 in every 9 children in the United States between the age of 3-17 have been diagnosed with attention deficit hyperactivity disorder (ADHD).
Additionally, in 2022, a report by the American public broadcasting organization revealed that nearly 7.1 million people (including kids) were diagnosed with ADHD.
Additionally, the window of treatment for children suffering from ADHD is also wide open, as it was also found by the study that the total number of children taking medications was only half the number of children diagnosed with ADHD. This highlights a wide gap of unmet actions and initiatives to spread the awareness about the condition, propelling the possibilities of market expansion.
Adoption of Novel Therapeutics
As the healthcare domain is witnessing instrumental strides towards technological advancements, the ADHD treatment market is also influenced. The market players like Akili are coming to the forefront and establishing a new benchmark in the ADHD treatment market. Akili Interactive, a prescription-based digital medicine company announced the 510k clearance of its phone-based video game in June 2024. The game is curated and designed to manage attention-deficit hyperactivity disorder (ADHD). As the first-ever video game for ADHD management, it showcased notable efficacy of 83% clinical response in clinical trials. Such innovations have great potential in improving patient health as well as create huge market demand and support the upward trajectory of the market in the forecast period.
Surge in Drug Approvals to Meet Rising Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Demand
With increasing awareness, the diagnoses incidence is collectively booming. The market value is further fuelled by the escalating number of drug approvals for effective management of the disease. In May 2024, the US Food and Drug Administration (FDA) gave a nod to Tris Pharma’s Onyda XR (clonidine hydrochloride) indicated for the treatment of attention deficit hyperactivity disorder (ADHD). The drug is the first ever and only liquid stimulant ADHD medication receiving FDA approval in the United States. It is a once-a-day extended-release oral suspension with nighttime dosing indicated as a monotherapy for pediatric patients 6 years and older. Such drug approvals by the regulatory authorities are anticipated to propel market growth in the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The EMR’s report titled “Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Age Group
Market Breakup by Gender
Market Breakup by Distribution Channel
Market Breakup by Region
Market Share by Treatment Type to Witness Substantial Growth
The market segmentation based on treatment type is broadly segmented into stimulants and non-stimulants. Stimulants are further divided into Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate and Lisdexamfetamine Dimesylate, whereas, non-stimulants include Atomoxetine, Bupropion, Guanfacine and Clonidine. The stimulants are expected to dominate the market segment as they are highly effective in managing ADHD among both children and adults. Stimulants are commonly preferred by medical professionals due to their proven efficacy in treating the condition and improving patient outcomes.
Based on region, the market report offers insights for the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India.
In the market segmentation based on region, the United States has the largest market share due to the rising incidence of the condition. The market share is also influenced by the heightened level of awareness among people about the ADHD condition. According to the data released by the U.S Centers for Disease Control and Prevention, 56.9% of children aged between 6-11 years, are currently receiving ADHD treatments.
The key features of the market report comprise clinical trial analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Tokyo, Japan, Takeda is a multinational pharmaceutical company. It is the third-largest pharmaceutical company in Asia. The company offers plasma-derived treatment therapies and vaccines focused on medical conditions such as oncology, rare diseases, neuroscience, and gastroenterology.
Aytu BioPharma, Inc. headquartered in Denver, Colorado, is a dynamic speciality pharmaceutical company with an expanding portfolio of prescriptions primarily focused on complex conditions such as ADHD and other common conditions.
Headquartered in Indiana, United States, Eli Lily and Company is a pharmaceutical company with an expanding foot reach in more than 125 countries. With primary drug offerings for conditions like diabetes, the company is also known for its clinical depression drugs like Prozac.
Headquartered in Manhattan, New York, Pfizer is a multinational pharmaceutical and biotechnology corporation. The company offers drugs and vaccines for the treatment of conditions such as immunology, oncology, cardiology, endocrinology, and neurology.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Noven Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Novartis AG, Curemark, LLC, Highland Therapeutics Inc., and GlaxoSmithKline Plc.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Age Group |
|
| Breakup by Gender |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share